Press release archive 2000

Wednesday, 20 December 2000
SENIOR APPOINTMENTS AT ASTRAZENECA AstraZeneca today announced the appointment of Bruno Angelici as Executive Vice President, International Sales and Marketing in succession to Mike O'Brien who is retiring.
Tuesday, 19 December 2000
ASTRAZENECA WINS LOSEC® PATENT LITIGATION IN CANADA The Federal Court of Canada has ruled in favour of AstraZeneca in litigation between AstraZeneca and RhoxalPharma Inc. under the Patented Medicines (Notice Of Compliance) Regulations.
Thursday, 14 December 2000
ASTRAZENECA GAINS JAPANESE APPROVAL FOR TWO MAJOR TREATMENTS - TWO MORE EXPECTED BEFORE YEAR END AstraZeneca today announced it has received approval from the Japanese Ministry of Health and Welfare (MWH) for Seroquel®, one of its major pharmaceuticals, and two significant line extensions for omeprazole, the company's largest product worldwide. In addition, AstraZeneca expects two further major new pharmaceuticals to be approved in Japan before the end of 2000.
Tuesday, 12 December 2000
ASTRAZENECA REPORTS CONTINUED STRONG PROGRESS ACROSS R&D PORTFOLIO AstraZeneca today presents an R&D update to a meeting of analysts, at its Mölndal site in Sweden.
Thursday, 7 December 2000
ASTRAZENECA RELEASES ENCOURAGING PHASE III DATA ON ICI182780 (FASLODEX®) - A NEW TYPE OF ADVANCED BREAST CANCER DRUG OFFERING A POTENTIAL NEW OPTION TO ONCOLOGY COMMUNITY Data presented today at the 23rd annual San Antonio Breast Cancer Symposium suggest that AstraZeneca's ICI182780 (Faslodex®) is at least as effective as Arimidex® , the most widely prescribed aromatase inhibitor, in treating advanced breast cancer in post-menopausal women who have failed initial hormonal treatment.
Tuesday, 21 November 2000
ASTRAZENECA FILES ZOMIG® NASAL SPRAY IN EUROPE AstraZeneca announced today that it has submitted its first regulatory application in Europe for Zomig (zolmitriptan) Nasal Spray for the acute treatment of migraine with or without aura. This new treatment will be reviewed under the Mutual Recognition procedure with Sweden acting as the reference member state. This is the first filing of a second-generation triptan for a nasal spray formulation.
Friday, 17 November 2000
SWEDISH COURT RULES IN ASTRAZENECA's FAVOUR IN OMEPRAZOLE SPC CASE AstraZeneca today announced that the Stockholm District Court has ruled that Scand Pharm's generic omeprazole product infringes AstraZeneca's Supplementary Patent Certificate (SPC) for omeprazole, which provides protection until November 15, 2002.
Wednesday, 15 November 2000
ASTRAZENECA REMAINS COMMITTED TO STROKE TREATMENT RESEARCH FOLLOWING STUDY FINDINGS FOR ZENDRA AstraZeneca today announced that development of Zendra (clomethiazole) has been stopped following analysis of findings from the Class-I study which showed no efficacy benefits for patients suffering acute cases of stroke.
Monday, 13 November 2000
SYNGENTA SHARES PRICED AT CHF 85 FOR GLOBAL SECONDARY OFFERING Not for distribution or release in whole or in part into or from the United States, Canada, Australia or JapanAstraZeneca announces that AstraZeneca, Novartis, Syngenta and the Joint Global Co-ordinators have set a price of CHF 85 per share (equivalent to approximately £33.65 and 479.88 SEK per share) and USD 9.63 per ADS for the Global Secondary Offering of Syngenta shares. The price per ADS is based upon the noon buying rate of the New York Federal Reserve Bank on 10 November 2000 of CHF 1.7657 to USD 1.
Monday, 13 November 2000
DEALINGS COMMENCE IN SYNGENTA AG AstraZeneca announces that dealings have commenced in shares of Syngenta AG.